Target intelligence / Profile preview

Amylin receptor 2 (AMY2R) (AMY2R)

Target
AMY2R
Molecular classification
G protein-coupled receptor, Class B GPCR, Heterodimeric receptor, Calcitonin receptor family
01

Overview

The Amylin receptor 2 (AMY2R) is a heterodimeric G protein-coupled receptor (GPCR) formed by the association of the calcitonin receptor (CTR) with the receptor activity-modifying protein 2 (RAMP2) [1, 6, 13]. As a member of the Class B GPCR family, it serves as a primary mediator for the physiological actions of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells [1, 11, 15]. Activation of AMY2R primarily stimulates the Gs-adenylyl cyclase pathway, increasing intracellular cyclic AMP (cAMP) levels to regulate glucose metabolism and energy balance [1, 13, 15]. Its biological roles include suppressing postprandial glucagon secretion, slowing gastric emptying, and promoting satiety through central nervous system signaling [2, 11, 15]. Consequently, AMY2R is a key therapeutic target for metabolic diseases such as type 2 diabetes and obesity, with drugs like the amylin analogue pramlintide and the dual agonist cagrilintide utilizing its pathways to improve glycemic control and induce weight loss [6, 12, 13]. Furthermore, the receptor is implicated in neurodegenerative conditions like Alzheimer's disease due to its ability to bind amyloid-beta peptides, suggesting potential roles beyond metabolic regulation [1, 14, 15].

Other names
AMY2AMY2 receptorCalcitonin receptor/RAMP2 complexCTR/RAMP2 heterodimer
02

Mechanism of action

Agonists bind to the AMY2R heterodimeric complex, activating Gs protein-mediated signaling which stimulates adenylyl cyclase to increase intracellular cyclic AMP (cAMP) levels, leading to the modulation of metabolic and neuroendocrine pathways.

03

Biological functions

Signal transductionRegulation of appetite and satietyGlucose homeostasisInhibition of gastric emptyingInhibition of glucagon secretionNutrient sensingDigestive regulation
04

Disease associations

Type 2 diabetes mellitusObesityAlzheimer's diseaseMigraine
05

Safety considerations

NauseaVomitingHypoglycemia (when co-administered with insulin)Peptide aggregationOff-target effects due to similarity with other calcitonin family receptors
06

Interacting drugs

Pramlintide

5 more in the full profile.

07

Biomarkers

HbA1cPostprandial glucose levelsBody weightGastric emptying ratePlasma amylin levels

Beyond the preview

Go deeper on Amylin receptor 2 (AMY2R) (AMY2R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amylin receptor 2 (AMY2R) (AMY2R).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call